
Cognitive Impairment Associated with Schizophrenia-CIAS-Pipeline Insight, 2024
Description
Cognitive Impairment Associated with Schizophrenia-CIAS-Pipeline Insight, 2024
DelveInsight’s, “Cognitive Impairment Associated with Schizophrenia-CIAS- Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cognitive Impairment Associated with Schizophrenia-CIAS pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cognitive Impairment Associated with Schizophrenia-CIAS: Overview
Schizophrenia is a serious mental disorder affecting approximately 1% of the US population and 24 million people worldwide. It is characterized by the occurrence of positive symptoms, such as hallucinations or delusions, and negative symptoms, such as affective flattening, and social withdrawal. Though schizophrenia affects a relatively small proportion of the population, it incurs substantial individual, societal, and healthcare costs. Cognitive deficits are not yet included in the diagnostic criteria for schizophrenia, but are considered a core feature of schizophrenia symptomatology. While neuropsychological impairment may not be present in all patients with schizophrenia, almost all patients with schizophrenia display some cognitive impairment in comparison with healthy controls. Cognitive impairments are often fully developed when patients present with a first episode of illness. Impairment occurs in most aspects of cognition, including attention, verbal learning and memory, secondary memory, working memory and executive functions. In most cases, cognitive impairments do not worsen or improve with illness progression. Treatments available for schizophrenia include typical and atypical antipsychotics, which predominantly target the positive symptoms of schizophrenia. Despite the availability of antipsychotic medications, patients with schizophrenia are often unsuccessful in re-entering the community and treatments do not appear to improve cognitive function beyond practice effects. Therefore, treatments for cognitive impairment have been identified as an unmet need. Cognitive deficits are one of the core symptoms of schizophrenia that evolve during the course of schizophrenia, after being originated even before the onset of illness.
""Cognitive Impairment Associated with Schizophrenia-CIAS- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cognitive Impairment Associated with Schizophrenia-CIAS pipeline landscape is provided which includes the disease overview and Cognitive Impairment Associated with Schizophrenia-CIAS treatment guidelines. The assessment part of the report embraces, in depth Cognitive Impairment Associated with Schizophrenia-CIAS commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cognitive Impairment Associated with Schizophrenia-CIAS collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cognitive Impairment Associated with Schizophrenia-CIAS R&D. The therapies under development are focused on novel approaches to treat/improve Cognitive Impairment Associated with Schizophrenia-CIAS.
This segment of the Cognitive Impairment Associated with Schizophrenia-CIAS report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cognitive Impairment Associated with Schizophrenia-CIAS Emerging Drugs
- RL-007: Recognify Life Sciences
- BIIB104: Biogen
- Luvadaxistat: Takeda
Further product details are provided in the report……..
Cognitive Impairment Associated with Schizophrenia-CIAS: Therapeutic Assessment
This segment of the report provides insights about the different Cognitive Impairment Associated with Schizophrenia-CIAS drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cognitive Impairment Associated with Schizophrenia-CIAS
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Cognitive Impairment Associated with Schizophrenia-CIAS pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Cognitive Impairment Associated with Schizophrenia-CIAS: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cognitive Impairment Associated with Schizophrenia-CIAS therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cognitive Impairment Associated with Schizophrenia-CIAS drugs.
Cognitive Impairment Associated with Schizophrenia-CIAS Report Insights- Cognitive Impairment Associated with Schizophrenia-CIAS Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:- How many companies are developing Cognitive Impairment Associated with Schizophrenia-CIAS drugs?
- How many Cognitive Impairment Associated with Schizophrenia-CIAS drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cognitive Impairment Associated with Schizophrenia-CIAS?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cognitive Impairment Associated with Schizophrenia-CIAS therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cognitive Impairment Associated with Schizophrenia-CIAS and their status?
- What are the key designations that have been granted to the emerging drugs?
- Recognify Life Sciences
- Biogen
- Takeda
- Hoffmann-La Roche
- Astellas Pharma
- RL-007
- BIIB104
- Luvadaxistat
- Basmisanil
- ASP4345
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Cognitive Impairment Associated With Schizophrenia-CIAS: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Cognitive Impairment Associated With Schizophrenia-CIAS– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase II/III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- RL-007: Recognify Life Sciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cognitive Impairment Associated With Schizophrenia-CIAS Key Companies
- Cognitive Impairment Associated With Schizophrenia-CIAS Key Products
- Cognitive Impairment Associated With Schizophrenia-CIAS- Unmet Needs
- Cognitive Impairment Associated With Schizophrenia-CIAS- Market Drivers and Barriers
- Cognitive Impairment Associated With Schizophrenia-CIAS- Future Perspectives and Conclusion
- Cognitive Impairment Associated With Schizophrenia-CIAS Analyst Views
- Cognitive Impairment Associated With Schizophrenia-CIAS Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.